Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 185,049 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NOT program Clear all

Conditions: Pancreatic Disease, Pancreatic Cancer, Pancreatic Cyst, Gastrointestinal Tumor, Bile Duct Diseases, Bile Duct Cancer, Lymph Node Disease, Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Cancer
Interventions: Endoscopic ultrasound examination; Device
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years to 100 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Depression, Obesity
Interventions: Weight loss treatment, Behavior therapy for depression, Health education counseling; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Smallpox
Interventions: ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 28 Years and older
Enrollment: 357 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 3
States / cities: Lenexa, Kansas • Springfield, Missouri • Pawtucket, Rhode Island

Conditions: Depression
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 13 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glabellar Lines
Interventions: Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Glendale, Arizona • Coral Gables, Florida • New Orleans, Louisiana + 2 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: Care Manager CM), ADHD Portal; Behavioral · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 12 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypotension, Labor Complication
Interventions: SCD; Device
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions: Busulfan, Fludarabine; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Alcohol Drinking in College
Interventions: Parent handbook, Coping with negative emotions, Problem-solving risky situations, Recovering from slips; Behavioral
Lead sponsor: University of Massachusetts, Amherst; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Amherst, Massachusetts

Conditions: Acute Ischemic Stroke From Large Vessel Occlusion
Interventions: ANA Funnel Catheter, Control; Device
Lead sponsor: Anaconda Biomed S.L.; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Jacksonville, Florida • Atlanta, Georgia • Park Ridge, Illinois + 8 more

Conditions: Hyperoxia
Interventions: 60% oxygen, 100% oxygen; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 85 Years
Enrollment: 48,262 participants
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anesthesia, Surgery With General Anesthesia, Noncardiac Surgery, Hypotension During Surgery, Acute Kidney Injury (AKI), Myocardial Injury After Noncardiac Surgery (MINS), Vasopressor
Interventions: Norepinephrine, Phenylephrine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: San Francisco, California • College Park, Maryland • Ann Arbor, Michigan + 6 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Ketamine, Naltrexone Pill, Placebo pill; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Inflammatory Response
Interventions: Pistachio group; Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 40 Years to 60 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions: pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: idronoxil; Drug
Lead sponsor: Kazia Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Pembrolizumab; Biological
Lead sponsor: Alfred Chung, MD; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Depression
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 32 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Post-COVID Postural Orthostatic Tachycardia Syndrome
Interventions: IgPro20, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 29 more

Conditions: Chronic Heart Failure
Interventions: Vepoloxamer, 5% dextrose in water; Drug · Other
Lead sponsor: Mast Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 2
States / cities: Detroit, Michigan • Tupelo, Mississippi

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: TD-4208, Tiotropium; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Easley, South Carolina

Conditions: Advanced Prostate Cancer
Interventions: Pelvic DCFPyL PET-MRI fusion or PET/MRI; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Richter's Syndrome, CLL
Interventions: Obinutuzumab, lenalidomide, HDMP; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope

Effectiveness of Behavioral Treatments for Obesity and Major Depression in Women

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Latino Teen Depression Treatment Study

A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

Communication to Improve Shared Decision-Making in ADHD

Pre-epidural Sequential Compression Devices (SCDs) to Prevent Hypotension During Labor

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

Promoting Maintenance of Change Following Brief Intervention for Alcohol Use

Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter

The Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy

Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses

The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

Pistachio Consumption on Inflammatory Markers and Lean Body Mass

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

Phenoxodiol in Treating Patients With Refractory Solid Tumors

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Latinx Teen Depression Treatment Study

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Evaluation of Vepoloxamer in Chronic Heart Failure

A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome